Lv6
3082 积分 2024-07-22 加入
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
14天前
已完结
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
14天前
已完结
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
17天前
已完结
Therapeutic cancer vaccines: are we there yet?
17天前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial
1个月前
已完结
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
3个月前
已完结
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
3个月前
已完结
Errors in Figure 1
3个月前
已关闭
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
3个月前
已完结
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
3个月前
已完结
皖公网安备34019202002308
